Brentuximab vedotin improves survival of pediatric patients with classical Hodgkin’s lymphoma:
Brentuximab vedotin improves survival of pediatric patients with classical Hodgkin’s lymphoma Hodgkin’s lymphoma is the most common malignancy in the age group of 15-19 years and accounts for 7% of all pediatric malignancies. Brentuximab vedotin has been recently approved by FDA to treat high-risk classical Hodgkin’s lymphoma (cHL) in pediatric patients. The addition of brentuximab […]
Paediatrics Update